Article Text

Download PDFPDF
Extended report
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE
  1. Cristina Rozo1,
  2. Yurii Chinenov2,3,
  3. Reena Khianey Maharaj1,
  4. Sanjay Gupta1,
  5. Laura Leuenberger1,
  6. Kyriakos A Kirou4,
  7. Vivian P Bykerk4,5,
  8. Susan M Goodman4,5,
  9. Jane E Salmon1,4,5,
  10. Alessandra B Pernis1,3,5
  1. 1Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, New York, USA
  2. 2Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, New York, USA
  3. 3David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, New York, USA
  4. 4Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA
  5. 5Department of Medicine, Weill Cornell Medical College, Cornell University, New York, New York, USA
  1. Correspondence to Dr Alessandra B Pernis, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021, USA; pernisa{at}hss.edu

Footnotes

  • Handling editor Tore K Kvien

  • JES and ABP contributed equally.

  • Contributors ABP was involved in overall study conception and design as well as providing critical input on data interpretation and drafting of the manuscript. JES was also involved in study concept and design, data interpretation and drafting of the manuscript. CR was involved in experimental design, carrying out experiments, data acquisition and analysis, and drafting of the manuscript. YC performed NanoString analysis, contributed to the statistical analysis and was involved in the drafting of the manuscript. RKM recruited patients with RA and HCs, performed PBMC isolations and was involved in data interpretation. SG performed ROCK assays and western blots. LL recruited patients with SLE. KAK provided patients with SLE. VPB and SMG provided critical input on data interpretation. All authors helped to critically revise the intellectual content of the manuscript and approved the final submission.

  • Funding The research was supported by a grant from the NIH to JES and ABP (5R21AR62252-2), a grant from the NIH to ABP (1R01AI083440, 5R01AR064883), a NIH Research Rheumatology Training grant to CR (T32AR007517), a American Heart Association grant to YC (11SDG5160006) and the Peter Jay Sharp Foundation and the David Z. Rosensweig Genomics Research Center.

  • Competing interests ABP and JES received an investigator-initiated grant from Kadmon Corporation.

  • Ethics approval HSS IRB.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Handling editor Tore K Kvien

  • JES and ABP contributed equally.

  • Contributors ABP was involved in overall study conception and design as well as providing critical input on data interpretation and drafting of the manuscript. JES was also involved in study concept and design, data interpretation and drafting of the manuscript. CR was involved in experimental design, carrying out experiments, data acquisition and analysis, and drafting of the manuscript. YC performed NanoString analysis, contributed to the statistical analysis and was involved in the drafting of the manuscript. RKM recruited patients with RA and HCs, performed PBMC isolations and was involved in data interpretation. SG performed ROCK assays and western blots. LL recruited patients with SLE. KAK provided patients with SLE. VPB and SMG provided critical input on data interpretation. All authors helped to critically revise the intellectual content of the manuscript and approved the final submission.

  • Funding The research was supported by a grant from the NIH to JES and ABP (5R21AR62252-2), a grant from the NIH to ABP (1R01AI083440, 5R01AR064883), a NIH Research Rheumatology Training grant to CR (T32AR007517), a American Heart Association grant to YC (11SDG5160006) and the Peter Jay Sharp Foundation and the David Z. Rosensweig Genomics Research Center.

  • Competing interests ABP and JES received an investigator-initiated grant from Kadmon Corporation.

  • Ethics approval HSS IRB.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.